Image
CME Snapshotâ„¢

Raising the Bar by Lowering the Target

Integrating PCSK9 Inhibitors Into Hypercholesterolemia Management

Clinical Practice Guidelines

2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

Stone NJ, et al. Circulation. 2014;129(25 suppl 2):S1-S45.

National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1-Full Report.

Jacobson TA, et al. J Clin Lipidol. 2015;9(2):129-169.

2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents.

Lloyd-Jones DM, et al. J Am Coll Cardiol. 2016;68(1):92-125.

2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways.

Lloyd-Jones DM, et al.J Am Coll Cardiol. 2017;70(14):1785-1822.

Recent Update to the US Cholesterol Treatment Guidelines A Comparison With International Guidelines.

Nayor M, Vasan RS. Circulation. 2016;133(18):1795-1806.

Clinical Assessment Tools

ASCVD Risk Estimator

A companion tool to the 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk and the 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults (Goff DC, et al. J Am Coll Cardiol. 2014;633(25 Pt B):2935-2959 and Goff DC, et al. Circulation. 2014:129(25 suppl 2):S49-S73).

Reynolds Risk Score

A framework for calculating heart and stroke risk for women and men (Ridker PM, et al. JAMA. 2007;297(6):611-619).

Patient Resources

Centers for Disease Control and Prevention

Educational materials for patients with high cholesterol.

American Heart Association

Resources on managing hyperlipidemia by controlling cholesterol and triglycerides.

The FH Foundation

A patient-centered nonprofit organization dedicated to education, advocacy, and research on familial hypercholesterolemia (FH).

Suggested Readings

American College of Cardiology Scientific Sessions & Expo

March 2018; Orlando, Florida.

Cardiovascular outcomes with alirocumab after acute coronary syndrome: results of the ODYSSEY Outcomes trial.

Steg P, et al. American College of Cardiology Scientific Sessions & Expo; March 2018; Orlando, FL. Late-Breaking Clinical Trial Session 401-08.

Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial.

Schwartz GG, et al. Am Heart J. 2014;168(5):682-689.

Evolocumab and clinical outcomes in patients with cardiovascular disease.

Sabatine MS, et al. N Engl J Med. 2017;376(18):1713-1722.

Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial.

Sabatine MS, et al. Am. Heart J. 2016;173:94-101.

Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia.

Goldberg AC, et al. J Clin Lipidol. 2011;5(suppl 3):S1-S8.

Management of familial hypercholesterolemia: a review of the recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia.

Robinson JG. J Manag Care Pharm. 2013;19(2):139-149.

Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.

Robinson JG, et al. N Engl J Med. 2015;372(16):1489-1499.

Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.

Sabatine MS, et al. N Engl J Med. 2015;372(16):1500-1509.

Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials.

Zhang XL, et al. BMC Med. 2015;13(123):1-18.

Activity
Hot Topics in Dyslipidemia

From the 2018 American College of Cardiology Scientific Sessions

Relevant Resources

Incretin-Based Therapies for Type 2 Diabetes

Mechanism-Based Strategies to Achieve Patient-Centered Care

Insulin Replacement Therapy for Type 2 Diabetes

Patient-Centered Management of Hyperglycemia in Primary Care

Improving Outcomes in Type 2 Diabetes

Integrating GLP-1 Receptor Agonists Into Multimodal Treatment Regimens

A Focus on Bipolar Depression

Overcoming Diagnostic Barriers and Optimizing Long-Term Patient Outcomes

Clinical Issues in Type 2 Diabetes

Discussions and Debates Around GLP-1 Receptor Agonists

Clinical Issues in Type 2 Diabetes

Evolving Roles of GLP-1 Receptor Agonists

Improving Outcomes for Women with Type 2 Diabetes

Individualizing Evidence-Based Care

Noninsulin Approaches to Managing Type 2 Diabetes

Best Practices in Combination Therapy

Hitting the Target in Type 2 Diabetes

Evolving Approaches to Insulin Based Therapy

Improving Outcomes in Congenital and Acquired Lipodystrophy

Best Practices in Diagnosis and Management

Clinical Updates in Type 2 Diabetes

New Strategies for Insulin Replacement Therapy

Clinical Issues in Type 2 Diabetes

Consensus and Controversies Around Intensifying Noninsulin Therapy

How Low Do You Go?

Clinical Updates in LDL-C Management

Incretin-Based Therapies For Type 2 Diabetes

Improving Comprehensive Patient Care

Clinical Updates in Type 2 Diabetes

An Evolving Role for Combinations of Injectable Antihyperglycemic Therapies